Day One Biopharmaceuticals
DAWN
DAWN was delisted on the 22nd of April, 2026.
184 hedge funds and large institutions have $747M invested in Day One Biopharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 41 funds opening new positions, 69 increasing their positions, 46 reducing their positions, and 21 closing their positions.
95% more first-time investments, than exits
New positions opened: 41 | Existing positions closed: 21
50% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 46
12% more funds holding
Funds holding: 164 → 184 (+20)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less ownership
Funds ownership: 92.95% → 92.94% (-0%)
6% less capital inflows, than outflows
Capital inflows: $164M | Capital outflows: $175M
30% less call options, than puts
Call options by funds: $1.23M | Put options by funds: $1.76M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Polar Capital Holdings
London,
United Kingdom
|
+$23.3M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
+$16.7M |
| 3 |
Vestal Point Capital
New York
|
+$12.5M |
| 4 |
Millennium Management
New York
|
+$12.2M |
| 5 |
Goldman Sachs
New York
|
+$11.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fairmount Funds Management
West Conshohocken,
Pennsylvania
|
-$39.3M |
| 2 |
TimesSquare Capital Management
New York
|
-$21.7M |
| 3 |
Braidwell
Stamford,
Connecticut
|
-$14.4M |
| 4 |
Janus Henderson Group
London,
|
-$13.8M |
| 5 |
First Turn Management
Del Mar,
California
|
-$12M |
DAWN Hedge Fund Activity: Q1 2025 in Review
184 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Day One Biopharmaceuticals (DAWN) for Q1 2025, worth a combined $747M — down 37% from $1.19B a quarter earlier.
Buyers outnumbered sellers: 41 funds opened new DAWN positions and 21 closed out — a net gain of 20 holders — while 69 added to existing stakes and 46 trimmed.
The largest buyer was Polar Capital Holdings, adding an estimated $23.3M. The largest seller was Fairmount Funds Management, exiting entirely with an estimated $39.3M sold.
- 184 institutional investors held Day One Biopharmaceuticals (DAWN) as of Q1 2025, up from 164 in Q4 2024.
- Funds reported $747M of Day One Biopharmaceuticals stock for Q1 2025, down 37% quarter-over-quarter.
- 41 funds opened new Day One Biopharmaceuticals positions in Q1 2025 and 21 closed out, a net change of +20 holders.
- The largest Day One Biopharmaceuticals buyer in Q1 2025 was Polar Capital Holdings, an estimated $23.3M added.
- The largest Day One Biopharmaceuticals seller in Q1 2025 was Fairmount Funds Management, an estimated $39.3M sold.
Based on aggregated 13F filings for Q1 2025.